Status:
UNKNOWN
Preclinical Project on the Traitment of Acute Lymphoblastique Leukemia With NVP-BEP800, an Inhibitor of the Heat Shock Protein HSP90
Lead Sponsor:
Centre Hospitalier Universitaire Dijon
Conditions:
Acute T Lymphoblastic Leukemia (T-ALL)
Acute B Lymphoblastic Leukemia (B-ALL)
Eligibility:
All Genders
18-80 years
Brief Summary
NVP-BEP800, a new HSP90 inhibitor, has particularly interesting therapeutic potential and represents hope in cancer pathologies. While it is currently being tested for solid cancers, no preclinical st...
Eligibility Criteria
Inclusion
- Patient suffering from acute lymphoblastic leukaemia whose biological samples are kept at the Biology Technical Platform.
Exclusion
- Patient over 80 years of age
Key Trial Info
Start Date :
November 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2021
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT04437420
Start Date
November 1 2019
End Date
September 1 2021
Last Update
June 23 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chu Dijon Bourgogne
Dijon, France, 21000